Name (Synonyms) | Correlation | |
---|---|---|
drug1236 | Hemanext One Wiki | 1.00 |
drug3208 | blood samples Wiki | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D009410 | Nerve Degeneration NIH | 0.71 |
D003141 | Communicable Diseases NIH | 0.08 |
D007239 | Infection NIH | 0.05 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0002383 | Encephalitis HPO | 1.00 |
HP:0002180 | Neurodegeneration HPO | 0.71 |
There is one clinical trial.
Emergence of Covid-19 virus is associated with high frequency of extremely severe clinical pictures, with minor signs of CNS impairment (e.g. anosmia, headache). Since neurotropism is a common feature of coronavirus infection in animals, the investigators examine if indirect signs of CNS lesion are observed in association with severe Covid-19 infection.
Description: Change of neurofilament light chain (NFL) (pg/ml) level between first day of hospitalisation and one week; and change of GFAP (pg/ml) level between first day of hospitalisation and one week.
Measure: Change of neurodegeneration markers level Time: Level of neurofilament light chain (NFL) is dosed at inclusion (day 0) and week 1. Level of GFAP is dosed at inclusion (day 0) and week 1 (day 7).